PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib
| Autor: | Stefan N. Constantinescu, Bengt Hallberg, Florence A. Arts, Christian Pecquet, Jean-Baptiste Demoulin, Amélie Velghe, D Chand |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Cancer Research Blotting Western Infantile myofibromatosis PDGFRB Biology medicine.disease_cause Cell Line Receptor Platelet-Derived Growth Factor beta 03 medical and health sciences Mice 0302 clinical medicine Cell Line Tumor Genetics medicine Animals Humans Molecular Biology Protein Kinase Inhibitors Growth Disorders Cell Proliferation Mice Knockout Mutation Mice Inbred BALB C Point mutation Myofibromatosis Neoplasms Experimental Oncogenes Syndrome medicine.disease 030104 developmental biology Imatinib mesylate Cell Transformation Neoplastic Nilotinib 030220 oncology & carcinogenesis Overgrowth syndrome Cancer research Imatinib Mesylate MCF-7 Cells Mutagenesis Site-Directed NIH 3T3 Cells Female Tyrosine kinase medicine.drug |
| Zdroj: | Oncogene. 35(25) |
| ISSN: | 1476-5594 |
| Popis: | Recently, germline and somatic heterozygous mutations in the platelet-derived growth factor receptor β (PDGFRB) have been associated with familial infantile myofibromatosis (IM), which is characterized by soft tissue tumors, and overgrowth syndrome, a disease that predisposes to cancer. These mutations have not been functionally characterized. In the present study, the activity of three PDGFRB mutants associated with familial IM (R561C, P660T and N666K) and one PDGFRB mutant found in patients with overgrowth syndrome (P584R) was tested in various models. The P660T mutant showed no difference with the wild-type receptor, suggesting that it might represent a polymorphic variant unrelated to the disease. By contrast, the three other mutants were constitutively active and able to transform NIH3T3 and Ba/F3 cells to different extents. In particular, the germline mutant identified in overgrowth syndrome, P584R, was a stronger oncogene than the germline R561C mutant associated with myofibromatosis. The distinct phenotypes associated with these two mutations could be related to this difference of potency. Importantly, all activated mutants were sensitive to tyrosine kinase inhibitors such as imatinib, nilotinib and ponatinib. In conclusion, the PDGFRB mutations previously identified in familial IM and overgrowth syndrome activate the receptor in the absence of ligand, supporting the hypothesis that these mutations cause the diseases. Moreover, imatinib seems to be a promising treatment for patients carrying these mutations. To our knowledge, these are the first confirmed gain-of-function point mutations of PDGFRB in human cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink